SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine

Behavioural Pharmacology

Volumn 10, Issue 4, 1999, Pages 429-432

  Masserano, J M ^a   Karoum, F ^a   Wyatt, R J ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Amphetamine; Apomorphine; Cannabinoid; Locomotor activity; SR 141716A

Indexed keywords

AMPHETAMINE; APOMORPHINE; CANNABINOID; CANNABINOID RECEPTOR ANTAGONIST; RIMONABANT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; RAT;

EID: 0032722267     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199907000-00010     Document Type: Article

References (21)

1. Bidaut-Russell M, Howlett AC (1991). Cannabinoid receptor-regulated cyclic AMP accumulation In the rat striatum. J Neurochem 57:1769-1773.
2. Cadogan AK, Alexander SP, Boyd EA, Kendall DA (1997). Influence of cannabinoids on electrically evoked DA release and cyclic AMP generation in the rat striatum. J Neurochem 69:1131-1137.
3. Compton DR, Aceto MD, Lowe J, Martin BR (1996). In vivo characterization of a specific cannabinoid receptor antagonist (SR 141716A): inhibition of delta-9-tetrahydrocannabinol-induced responses and apparent agonist affinity. J Pharmacol Exp Ther 277:586-594.
4. de Miguel R, Romero J, Munoz RM, Garcia-Gil L, Gonzalez S, Villanua MA et al. (1998). Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs. Biochem Pharmacol 56:1331-1338.
5. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613.
6. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
7. Herkenham M, Lynn AB, de Costa BR, Richfield EK (1991). Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547:267-274.
8. Howlett AC (1995). Pharmacology of cannabinoid receptors. Ann Rev Pharmacol Toxicol 35:607-634.
9. Howlett AC, Johnson MR, Melvin LS, Milne CM (1988). Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol 33:297-302.
10. Lichtman AH, Martin BR (1996). Delta-9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology (Berl) 126:125-131.
11. Klitenick MA, Tham CS, Fibiger HC (1995), Cocaine and d-amphetamine increase c-fos expression in the rat cerebellum. Synapse 19:29-36.
12. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 326:561-564.
13. Narayanan S, Wallace L, Uretsky N (1996). Spontaneous and drug-stimulated locomotor activity after the administration of pertussis toxin into the ventral tegmental area. J Psychiatry Neurosci 21:172-180.
14. Ogren SO, Hall H, Kohler C, Magnusson O, Sjostrand SE (1986). The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90:287-294.
15. Petry N, Furmidge L, Tong ZY, Martin C, Clark D (1993). Time sampling observation procedure for studying drug effects: interaction between d-amphetamine and selective doparnine receptor antagonists in the rat. Pharmacol Biochem Behav 44:167-180.
16. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C et al. (1994). SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350 240-244.
17. Rinaldi-Carmona M, Barth F, Heaulme M, Alonso R, Shire D, Congy C et al. (1995), Biochemical and pharmacological characterization of SR 141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56:1941-1947.
18. Semba K, Fibiger HC, Vincent SR (1987). Neurotransmitters in the mammalian striatum: neuronal circuits and heterogeneity. Can J Neurol Sci 14:386-394.
19. Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH (1998). Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A. J Pharmacol Exp Ther 286: 697-703.
20. Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R (1993). Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem 61:353-355.
21. 9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats. Eur J Pharmacol 250:205-208.